Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.44 |
| ▸ | PARK7 | Q99497 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13627924 | 0.88 | CA12 (0.49) | CA12CA1CA2CA9LMNA | |
| SCHEMBL13627934 | 0.88 | UCHL3 (0.50) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL13627907 | 0.88 | CA1 (0.49) | CHRM5CA12CA1CA2CA9 | |
| SCHEMBL13627898 | 0.87 | ALDH1A1 (0.50) | CA12CA1CA2CA9PIM1 | |
| SCHEMBL13627973 | 0.85 | CHRM5 (0.47) | CHRM5CA12CA1CA2CA9 | |
| SCHEMBL13627936 | 0.85 | TRPA1 (0.62) | CHRM5TRPA1PARK7TSHRALDH1A1 | |
| SCHEMBL13627949 | 0.84 | ACHE (0.55) | CHRM5CA12CA1CA2CA9 | |
| SCHEMBL13627916 | 0.84 | CASP1 (0.51) | CA12CA1CA2CA9LMNA | |
| SCHEMBL13627937 | 0.82 | CHRM5 (0.55) | CHRM5CA12CA1CA2CA9 | |
| SCHEMBL13627946 | 0.81 | UBE2N (0.56) | CHRM5CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612065-B2 | Inhibitors of c-JUN N-terminal kinases (JNK) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612065-B2 | Inhibitors of c-JUN N-terminal kinases (JNK) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | SALITURO FRANCESCO G | 2008-02-07 | — | — | US | disclosed |
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | SALITURO FRANCESCO G | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | MAP3K1, JUN, MAP3K7 | CHRM5 4815/4885CA12 4791/4885CA1 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.